Frequency and time in years to reaching a T2T state during the follow-up period
| Total cohort (N=165) | LN group (N=45) | No-LN group (N=120) | P value LN group versus no-LN group* | |||||
| n (% of N) | Median (25th, 75th percentiles) time to event | n (% of N) | Median (25th, 75th percentiles) time to event | n (% of N) | Median (25th, 75th percentiles) time to event | Frequency of event | Median time to event | |
| Presence of SLEDAI-LD | 159 (94) | 0 (0, 0.24) | 40 (89) | 0.23 (0, 0.61) | 119 (99) | 0 (0, 0) | 0.002 | <0.0001 |
| Low-CS | 151 (92) | 0 (0, 0.67) | 37 (82) | 0.28 (0, 1.65) | 114 (95) | 0 (0, 0.41) | 0.009 | <0.0001 |
| Presence of LLDAS | 132 (80) | 0.53 (0, 1.61) | 30 (67) | 1.11 (0.49, NE) | 102 (85) | 0.27 (0, 1.00) | 0.009 | <0.0001 |
| Presence of any T2T state | 161 (98) | 0 (0, 0) | 42 (93) | 0 (0, 0.48) | 119 (99) | 0 (0, 0) | 0.03 | <0.0001 |
*P values are from χ2 test or Fisher’s exact test as appropriate, or −2 log-rank test.
CS, corticosteroid; LLDAS, lupus low disease activity state; LN, lupus nephritis; low-CS, limited corticosteroid use; NE, not estimable; SLEDAI-LD, SLEDAI score of <4; T2T, treat-to-target.